1.
Open Forum Infect Dis
; 11(5): ofae223, 2024 May.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38756765
RESUMEN
This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.